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Background: The implementation of Medicare part D on January 1,
2006 required all adults who were dually enrolled in Medicaid and
Medicare (dual eligibles) to transition prescription drug coverage from
Medicaid to Medicare part D. Changes in payment systems and uti-
lization management along with the loss of Medicaid protections had the
potential to disrupt medication access, with uncertain consequences for
dual eligibles with human immunodeficiency virus (HIV) who rely on
consistent prescription coverage to suppress their HIV viral load (VL).
Objective: To estimate the effect of Medicare part D on self-
reported out-of-pocket prescription drug spending, AIDS Drug
Assistance Program (ADAP) use, antiretroviral adherence, and HIV
VL suppression among dual eligibles with HIV.
Methods: Using 2003–2008 data from the Women’s Interagency
HIV Study, we created a propensity score–matched cohort and
used a difference-in-differences approach to compare dual eligibles’
outcomes pre-Medicare and post-Medicare part D to those enrolled
in Medicaid alone.
Results: Transition to Medicare part D was associated with a sharp
increase in the proportion of dual eligibles with self-reported out-of-
pocket prescription drug costs, followed by an increase in ADAP
use. Despite the increase in out-of-pocket costs, both adherence and
HIV VL suppression remained stable.
Conclusions: Medicare part D was associated with increased out-of-
pocket spending, although the increased spending did not seem to com-
promise antiretroviral therapy adherence or HIV VL suppression. It is
possible that increased ADAP use mitigated the increase in out-of-pocket
spending, suggesting successful coordination between Medicare part D
and ADAP as well as the vital role of ADAP during insurance transitions.
Key Words: HIV, AIDS Drug Assistance Program, ADAP, anti-
retroviral therapy, Medicare part D, Medicaid, dual eligible
(Med Care 2018;56: 47–53)
More than half of US adults with human im-munodeficiency virus (HIV) (56%) receive health in-
surance coverage through Medicare or Medicaid.1 Medicare
is a federally administered program that provides health in-
surance to Americans aged 65 and above, as well as persons
with permanent disabilities under age 65, who receive Social
Security Disability Insurance.2 Medicaid is state-run and
provides health insurance to certain categories of low-income
persons.3 In total 10% of adults with HIV meet eligibility
criteria for both Medicare, primarily through disability criteria
rather than age, and Medicaid, through a combination of in-
come and disability criteria, and are enrolled in both programs
(dual eligibles).4 For dual eligibles, Medicare provides pri-
mary coverage, whereas Medicaid absorbs remaining costs
and covers services not available through Medicare.3 In ad-
dition to Medicaid and Medicare, AIDS Drug Assistance
Programs (ADAP) serve as a safety net program, providing
prescription drugs to low-income individuals with limited
prescription drug coverage.5 People with HIV rely on these
programs for consistent access to antiretroviral therapy
(ART), which is crucial for maintaining HIV viral load (VL)
suppression.6
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For Medicaid enrollees, most states offer a prescription 
drug benefit with a broad formulary with little to no cost-
sharing, including protections that allow enrollees to obtain 
prescriptions without a copayment, based on ability to pay.7 
Before implementation of Medicare part D in 2006, Medicare 
coverage did not include a prescription drug benefit and dual 
eligibles received prescription drug coverage through Med-
icaid. Since then, prescription drug coverage has shifted from 
Medicaid to Medicare and dual eligibles were required to 
enroll (or be auto-enrolled) in Medicare part D for pre-
scription drug coverage at implementation.8
Medicare part D is administered by private prescription 
drug plans that mandate cost-sharing and vary in the lists of 
covered drugs and rules for accessing those drugs (utilization 
management).7,9 Before Medicare part D implementation, 
policy analysts anticipated that the transition would disrupt 
ART use for people with HIV in the short term, and in the 
long term due to increased cost-sharing as their coverage 
through Medicaid was replaced by Medicare part D.7 Among 
people with HIV, disruptions in ART can lead to decreased 
ART adherence and viral suppression, which promote HIV-
related morbidity and mortality.10
Among the general population of dual eligibles sur-
veyed in Kansas following Medicare part D implementation, 
20% of dual eligibles reported difficulties filling prescriptions 
after the transition to Medicare part D.11 Difficulties filling 
prescriptions included paying more out-of-pocket for pre-
scription drugs than under Medicaid, needing drugs not 
covered on their plan’s formulary, and delayed auto-
enrollment into Medicare part D drug plans.11
Only 2 cross-sectional studies have examined the 
effects of Medicare part D on people with HIV, shortly after 
implementation. One study found that the odds of ART in-
terruption were 6 times higher among those covered by 
Medicare part D compared with those with other or no 
insurance.12 Increased cost was the primary barrier associated 
with ART interruption. These findings are supported by re-
ports from HIV providers that the most patients had diffi-
culties accessing their prescription drugs under Medicare part
D.13 Despite reported ART interruption, no studies have ex-
amined the effects of Medicare part D on HIV clinical out-
comes, such as viral suppression. Out-of-pocket spending on 
prescription drugs was of interest because reports of dual 
eligibles with HIV linked increases in out-of-pocket cost to 
ART interruption after Medicare part D,12 even though re-
search on the elderly Medicare population indicated improved 
medication access after Medicare part D.14 Further, no studies 
have examined effects of Medicare part D implementation on 
ADAP use, despite reported coordination between Medicare 
part D and ADAP.15 The effects on ADAP are of interest 
because, in addition to providing prescription drugs, ADAP 
can also support people who have certain types of pre-
scription drug coverage, but still face financial barriers to 
accessing their medications, such as individuals under Med-
icare part D.15 The implementation of Medicare part D also 
has similarities to the implementation of the Affordable Care 
Act (ACA) in 2014. Medicare part D is analogous to the ACA 
in that individuals with HIV may transition from Medicaid’s 
prescription drug coverage to private prescription drug
coverage, through part D drug plans under Medicare part D 
and under qualified health plans through the ACA’s Health 
Insurance Exchanges. Medicare part D and the ACA are also 
similar in that the private coverage cofunctions with 
ADAP,16,17 mirroring ADAP’s cofunctioning with Medicare 
part D.15
This study is the first to estimate the effects of Medicare 
part D on out-of-pocket prescription drug spending, ADAP 
use, ART adherence, and viral suppression in dual eligibles 
with HIV. We used data from the Women’s Interagency HIV 
Study (WIHS), which include laboratory measures of HIV 
VL and are collected independent of insurance or pharmacy 
use, an advantage over clinic or pharmacy claims data.
METHODS
Data Source
The WIHS is the largest multisite prospective cohort 
study of HIV-seropositive and HIV-seronegative women in 
the United States.18,19 During the time frame for this analysis 
(2003–2008), the 6 WIHS study sites were located in the 
Bronx, NY; Brooklyn, NY; Washington, DC; San Francisco, 
CA; Los Angeles, CA; and Chicago, IL. Since enrollment 
began in 1994, the WIHS has collected data on 3679 HIV-
seropositive participants. Biannual study visits include a 
physical examination, laboratory measurements, and behav-
ioral questionnaires.
Design and Study Sample
We estimated changes in out-of-pocket prescription drug 
spending, ADAP use, ART adherence, and viral suppression of 
dual eligibles after Medicare part D implementation, compared 
with a matched sample of Medicaid-only enrollees. We ex-
cluded women who missed 3 consecutive visits between 2003 
and 2008. We restricted the analysis to participants who (1) 
were HIV-seropositive by January 1, 2003, (2) had atleast 1 visit 
in both 2005 and 2006, and (3) reported Medicaid-Medicare 
dual eligibility or Medicaid-only enrollment at Medicare 
part D implementation on January 1, 2006. Among 1634 
HIV-seropositive participants, 1449 (87%) women had atleast 
1 visit in 2005 and in 2006. Among those, 801 women met the 




The exposure of interest was the transition to Medicare 
part D. Participants reporting dual eligibility in 2005 were 
considered dual eligible at Medicare part D implementation 
on January 1, 2006. The control group included participants 
reporting only Medicaid coverage and no other insurance in 
2005. We selected Medicaid-only participants because the 2 
groups had identical prescription drug coverage through 
Medicaid in the pre-Medicare part D period.
Outcomes of Interest
Several outcomes were considered: (1) self-reported out-
of-pocket spending on prescription drugs; (2) self-
reported
covariate balance between dual eligibles and the matched
control group was evaluated by comparing standard differ-
ences of means and t test statistics. We included baseline
(pre-Medicare part D) values for the following variables in
the logistic regression models to create propensity scores:
age at visit, race/ethnicity, education, employment, ADAP
use, out-of-pocket prescription drug spending, and HIV VL.
Continuous variables (age, VL) were included in the logistic
regression as splines25 and categorical variables were dicho-
tomized. We used the psmatch2 program in Stata to perform
the 1:1 match.20,26
We estimated the effects of Medicare part D im-
plementation on dual eligibles with HIV using a difference-
in-difference (DiD) approach in a propensity score–matched
cohort.27 The DiD approach compares the average changes
from pre-Medicare to post-Medicare part D in dual eligibles,
the group that was affected by the transition, to the average
changes during the same time period in participants with
Medicaid only, a group unaffected by Medicare part D. The
resulting “difference-in-differences” can be attributed to
the policy change, if the assumption of parallel trends is met,
the 2 groups can be balanced on baseline covariates, and there
is sufficient overlap in the propensity scores between the
groups. Linear regression was used to estimate the change in
the proportion of participants experiencing outcomes of
interest. Our Medicaid-only control group allowed us to
estimate changes in the outcomes of dual eligibles while
controlling for temporal trends that are common to both
groups (eg, advances in ART over time).
Finally, we performed sensitivity analyses to test the
assumptions inherent in propensity score matching and DiD
analyses. We explored the parallel trends assumption using
the Lowess plots, tested the balance of baseline covariates,
and quantified propensity score overlap of the 2 groups.
Sensitivity analyses included abbreviating pre-Medicare and
post-Medicare part D time periods (ie, restricting to the
2004–2007 and 2005–2006 time periods), examining ART
adherence at <95% versus ≥ 95% adherent, restricting to
individuals on ART, and specifying different covariate sets in
the propensity score model. All statistical analyses were
performed using Stata 13 (StataCorp, College Station, TX).
RESULTS
A total of 801 women were included in this analysis, of
which 125 (16%) were dual eligible and 676 (84%) with
Medicaid only (Table 1). Median age of dual eligibles was
higher than Medicaid-only participants (47; interquartile range:
41, 52 vs. 43; interquartile range: 38, 49, respectively). All
participants were under age 65, indicating that dual eligibles
became eligible for Medicare coverage through disability
criteria, rather than age. Among dual eligibles, 57% were
African-American, compared with 68% of Medicaid-only
participants. In 2005, 10% of dual eligibles participated in
ADAP, compared with the 5% of Medicaid-only participants
who participated in ADAP, similar to reports by the National
ADAP Monitoring Project.15 A greater proportion of dual
eligibles had completed high school or higher compared to
Medicaid-only participants (76% vs. 48%); and a lower
ADAP use; (3) self-reported ART adherence, and (4) HIV viral 
suppression.
Participants self-reported out-of-pocket prescription drug 
spending in the last 6 months at every biannual study visit 
(“none,” “< $25,” “$25–$200,” “$201–$500,” “> $500”). In 
2005, less than a quarter of participants (23%) indicated any 
out-of-pocket spending, and spending was collapsed to a binary 
indicator for any out-of-pocket prescription drug spending 
versus none. We selected a binary measure of out-of-pocket 
costs because even small cost-sharing increases in have been 
associated with changes in drug utilization in low-income 
patients.20,21
We also examined ADAP use, and participants reported 
whether they used ADAP at each visit. ADAP use was coded 
as a binary indicator for any use versus none since the last 
study visit. A comparison of WIHS data to matched medical 
record data supports the use of self-reported insurance type as 
a valid indicator of actual insurance coverage.22
Self-reported ART adherence was assessed as the cat-
egorical response to the survey question “Over the past 
6 months, how often did you take your antiretrovirals as 
prescribed?” where ART adherence was categorized as 
“100% of the time,” “95%–99% of the time,” “75%–94% of 
the time,” and “ < 75% of the time.” ART adherence was 
coded as a binary variable, indicating either <100% or 100%
adherence since last visit. We also examined an alternative
definition of adherence, ≥ 95% versus <95%. VL measure-
ments were taken every 6 months using the NucliSens assay 
(Organon Teknika Corp.), which had a lower limit of de-
tection of 80 copies/mL. We defined viral suppression as HIV
VL ≤ 200 copies/mL.23 All outcome measures and covariates 
were collected every 6 months throughout the study period.
Statistical Analysis
We explored the relationship between Medicare part D 
and outcome variables using a segmented locally weighted 
smoothed spline (Lowess)24 to visualize trends nonpara-
metrically. We allowed for inflection points at Medicare part 
D implementation on January 1, 2006 to visualize dis-
continuities associated with the transition. A Lowess plot fits 
a polynomial at each time point using weighted least squares, 
“smoothing” the outcome levels between data points.
Propensity Score Matching
We created a propensity score–matched cohort in which 
we matched dual eligibles with Medicaid-only participants. 
Under the assumption that the propensity score model was 
specified correctly, propensity scores should balance co-
variates between the 2 groups in the pre-Medicare part D 
period, strengthening the assumption that the matched Med-
icaid-only group represents an appropriate counterfactual for 
dual eligibles, had that group not transitioned to Medicare 
part D.
We used logistic regression to create propensity scores, 
with dual eligibility as the dependent variable and potential 
confounders as independent variables. We used a 1:1 nearest 
neighbor matching approach, without replacement, and dual 
eligibles were matched with the Medicaid-only participants 
with the propensity score that was nearest to their own. The
TABLE 1. Baseline Characteristics of Medicaid-Medicare Dual Eligibles and Medicaid-only Participants, Women’s Interagency HIV
Study (2005)









Age [median (IQR)] (y) 47 (41, 52) 43 (38, 49) 0.005 46 (41, 52) 46 (41, 52) 0.603
African American (%) 56.5 67.9 0.014 59.0 64.4 0.394
Hispanic ethnicity (%) 24.2 26.6 0.575 23.9 23.7 0.971
WIHS site (%)
Bronx 15.2 28.7 0.002 16.1 23.7 0.144
Brooklyn 20.0 23.5 0.391 20.3 16.9 0.506
Washington, DC 08.0 08.6 0.831 08.5 11.9 0.391
Los Angeles 20.0 11.0 0.005 19.5 15.3 0.393
San Francisco 24.0 15.1 0.014 22.0 17.8 0.417
Chicago 12.8 13.2 0.912 13.6 14.4 0.852
ADAP 10.4 05.1 0.019 07.7 07.6 0.985
Any out-of-pocket prescription
spending (%)
22.8 12.9 0.004 21.6 14.5 0.165
100% ART adherent† 51.2 43.2 0.127 51.2 48.4 0.719
CES-D [median (IQR)] 14 (3.5, 28.5) 15 (6, 25) 0.844 14 (3, 27) 15 (4, 27) 0.698
Household income <$12,000/y (%) 62.1 67.1 0.278 62.2 60.9 0.849
Graduated high school (%) 76.4 48.1 < 0.0001 25.5 27.0 0.792
Employed (%) 12.9 18.6 0.129 12.1 10.0 0.558
CD4 cell count [median (IQR)] 466 (312, 643) 416 (249, 622) 0.265 484 (324, 658) 476 (316, 728) 0.396
Virally suppressed (%)‡ 59.3 48.0 0.021 59.6 64.7 0.447
*Statistical significance tested using t tests.
†Proportions calculated within subset of dual eligibles (n= 103) and Medicaid-only participants (n= 461) on ART.
‡Viral suppression corresponds to a VL measurement of <200 copies/mL.
ADAP indicates AIDS Drug Assistance Programs; ART, antiretroviral therapy; CES-D, Center for Epidemiologic Studies Depression Scale; HIV, human immunodeficiency virus;
IQR, interquartile range; WIHS, Women’s Interagency HIV Study.
proportion of dual eligibles reported an annual household 
income of <$12,000 compared with those with Medicaid only 
(62% vs. 67%). Finally, a greater proportion of dual eligibles 
were virally suppressed, compared with Medicaid-only 
participants (59% vs. 48%), despite similar ART use and 
ART adherence levels.
Following Medicare part D implementation, Lowess 
plots showed a sharp increase in out-of-pocket prescription 
drug spending in 2006 (Fig. 1A). Although reported out-of-
pocket spending decreased over the following 2 years, dual 
eligibles’ out-of-pocket spending did not return to pre-
Medicare part D levels. Lowess plots showed a more gradual 
increase in ADAP use among dual eligibles (Fig. 1B).
Lowess plots of ART adherence showed no inflection 
points for either group. Viral suppression seemed to be in-
creasing over time in both groups, possibly corresponding to 
advances in ART, with no discontinuity following Medicare part 
D implementation (Figs. 1C, D). Lowess plots also indicated 
that the parallel trend assumption held for all outcomes of 
interest during the pre-Medicare part D time period, 
strengthening the validity of the DiD analyses. For all Lowess 
plots, atleast 93% of the analytic sample contributed data to each 
time point. In the analytic sample, the proportion of missing 
values was below 6% at Medicare part D implementation for all 
outcome measures and covariates, and below 7% throughout the 
full study period, with the exception of out-of-pocket 
prescription drug spending, which rose to 13% in 2008.
The set of variables used in the propensity score 
matching resulted in a covariate balance between the 2 groups 
on sociodemographics, medication use and related spending,
and health status (Table 1). In the propensity score–matched 
DiD analyses, dual eligibles showed increases in out-of-pocket 
spending on prescription drugs, with 23% reporting any out-of-
pocket spending for prescription drugs in the pre-Medicare part 
D period to 41% in the post-Medicare part D time period 
(Table 2). Adjusting for any temporal trends by subtracting the 
change in the matched control group, the DiD estimate attributed 
to the transition to Medicare part D was an average 20% change 
(95% confidence interval: 12%–27%) in proportion of dual 
eligibles reporting out-of-pocket spending. ADAP use increased 
by 10% among dual eligibles following Medicare part D 
implementation (95% confidence interval: 3%–18%).
Levels of self-reported ART adherence were comparable 
in dual eligibles and Medicaid-only enrollees in the pre-Medi-
care part D time period (47% vs. 39%) and in the post-Medicare 
part D time period (48% vs. 44%), and DiD estimation did not 
attribute a significant change to the transition. Sensitivity anal-
yses using other adherence cut-points did not alter these results. 
Similarly, DiD estimation did not attribute a significant change 
in the proportion of dual eligibles who were virally suppressed, 
after adjusting for temporal trends. Finally, the number of dual 
eligibles could not support subanalyses by ADAP use and re-
striction to participants on ART did not substantially change the 
direction or magnitude of any of the outcome variables.
DISCUSSION
This is the first study to examine the effects of Medicare 
part D implementation on out-of-pocket prescription medi-
cation costs, ART adherence, viral suppression, and ADAP 
use
among HIV-seropositive women enrolled in Medicaid and
Medicare (dual eligibles). As anticipated, the proportion of dual
eligibles reporting out-of-pocket spending for prescription drugs
increased following Medicare part D implementation. Despite
this increase, ART adherence and viral suppression remained
stable after the transition. The proportion of dual eligibles using
ADAP also increased after implementation, though the increase
was more gradual. Taken together, these results suggest that
while the transition to Medicare part D was associated with
increased self-reported out-of-pocket costs and ADAP use,
ART adherence and viral suppression remained stable.
Cost-sharing and Out-of-Pocket Prescription
Drug Spending
Our findings differed from previous research that reported
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FIGURE 1. A–D, Change in proportion of outcome of interest, by insurance type, time period in the Women’s Interagency HIV
Study (WIHS). ADAP indicates acquired immune deficiency syndrome Drug Assistance Program; ART; antiretroviral therapy; HIV,
human immunodeficiency virus.
TABLE 2. Difference-in-Differences Estimates—Average Proportion Change in Pre-Medicare and Post-Medicare Part D Time Period,
by Insurance Type, Women’s Interagency HIV Study 2003–2008
With OOP Spending (%) Using ADAP (%) ART Adherent (%)* Virally Suppressed (%)
% SE P % SE P % SE P % SE P
Pre-Medicare part D (2003–2005)
Medicaid Only 0.23 0.13 0.39 0.50
Dual eligible 0.24 0.14 0.47 0.55
Difference 0.01 0.04 0.859 0.01 0.04 0.716 0.08 0.05 0.155 0.05 0.05 0.361
Post-Medicare part D (2006–2008)
Medicaid Only 0.21 0.10 0.44 0.62
Dual eligible 0.41 0.22 0.48 0.66
Difference 0.20 0.04 < 0.001 0.12 0.04 0.004 0.04 0.05 0.440 0.05 0.05 0.337
Difference-in-differences 0.20 0.04 < 0.001 0.10 0.04 0.007 −0.04 0.05 0.440 −0.001 0.05 0.987
*Proportion reporting 100% ART adherence.
ADAP indicates AIDS Drug Assistance Program; ART, antiretroviral therapy; HIV, human immunodeficiency virus; OOP, out-of-pocket; VL, viral load.
costs in either the transition or the stable period following
Medicare part D implementation.28 However, those study
results were based on a sample of dual eligibles who were
> 65 years of age, whose health needs differ from nonelderly
populations with HIV. Our findings are supported by the 1
previous study of HIV-seropositive individuals, in which 60%
of those enrolled in a Medicare part D prescription drug plans
reported increased out-of-pocket prescription drug expenditures
shortly after implementation.12
ADAP Use and Medicare Part D
Lowess plots indicate an increase in ADAP use fol-
lowing the increase in out-of-pocket prescription drug 
spending. These findings are supported by reports of coor-
dinated coverage of dual eligibles through Medicare part D 
and ADAP.15 Despite the rise in ADAP use and the financial 
advantages of using ADAP in combination with Medicare 
part D, only 22% of dual eligibles in this study reported 
ADAP use and 41% still reported out-of-pocket prescription 
drug spending in 2008.
ART Adherence and Viral Suppression
Given reports of ART interruption and increased out-
of-pocket prescription drug costs shortly after Medicare part 
D implementation,12,13 we hypothesized that increased out-
of-pocket prescription drug spending would lead to decreased 
ART adherence, and consequently, decreased viral sup-
pression. However, dual eligibles’ ART adherence remained 
stable. There are several explanations for stable ART adher-
ence. First, increased enrollment in ADAP may have miti-
gated the effects of prescription drug spending by absorbing 
out-of-pocket-costs, resulting in stable ART adherence. Sec-
ond, despite increases in the proportion of dual eligibles with 
any out-of-pocket prescription drug spending, the bulk of 
participants reported low out-of-pocket spending. For persons 
with out-of-pocket costs, 54% of participants reported out-of-
pocket costs ranging from $1 to $25, and 42% had costs 
ranging from $26 to $200 in the prior 6 months. Even though 
two-thirds (66%) of participants reported a household income 
<$12,000 per year, costs may not have been high enough to 
lead to cost-related ART nonadherence. Finally, we also 
considered that the burden of out-of-pocket spending may 
have led to reduced spending on other essential needs (eg, 
food, child care) 29 or that WIHS participants may have been 
more conscientious about adherence due to their long-term 
study involvement.30
Similarly, we found no evidence of changes in viral 
suppression in dual eligibles associated with Medicare part D. 
Although the proportion of dual eligibles who were virally 
suppressed increased between the pre-Medicare and post-
Medicare part D time periods, a similar trend was observed in 
the Medicaid-only group, indicating that both groups bene-
fited from improvements in ART. These results suggest that 
stable viral suppression may have resulted from increased 
ADAP use, rather than improved medication access through 
Medicare part D. This interpretation is supported by studies in 
which ADAP was associated with an increased ART use31 
and increased likelihood of viral suppression.22
Limitations
Out-of-pocket costs, ART adherence, and ADAP use 
are self-reported in the WIHS over a period of 6 months, 
which may have led to misclassification. Our study was also 
limited to dual-eligible women with HIV who participate in a 
longitudinal cohort study, and results may not be general-
izable to all dual eligibles with HIV. Even though the WIHS 
is the largest observational cohort of women with HIV, the 6 
WIHS sites represent a limited number of US states, and the 
transition from state-run Medicaid programs to Medicare part 
D in this study may not be generalizable to all US states. 
Propensity scores can only balance groups on measured co-
variates, and, as in all observational studies, unmeasured 
covariates may confound our results. Finally, dual eligibles 
make up a small proportion of people with HIV and, con-
sequently, this study’s sample size was relatively small. 
However, even though dual eligibles represent a small pro-
portion of Medicare enrollees and our sample size was lim-
ited, their unique health care utilization and comorbidity 
patterns make their study significant.
Despite these limitations, this study has several unique 
advantages: study visits occur at 6-month intervals and are in-
dependent of insurance status or prescription fill behavior. Fur-
ther, study visits are standardized, and, as such, the WIHS cohort 
is consistently characterized over time. This study has an addi-
tional advantage that it assessed viral suppression, a key indicator 
of effective HIV treatment. Finally, this study’s longitudinal 
design allows analysis of dual eligibles over time, for several 
years before and after Medicare part D implementation.
CONCLUSIONS
Prior studies showed improved medication access fol-
lowing Medicare part D implementation in many Medicare 
enrollees. However, dual-eligible women with HIV, an un-
derstudied group, did not reflect those improvements in 
medication access or reduced out-of-pocket prescription drug 
costs seen in other Medicare enrollees. Our results underscore 
the importance of considering ADAP’s role in maintaining 
medication access and viral suppression during federally 
mandated insurance coverage transitions. Although ADAP is 
essential in providing HIV medications to the uninsured, it 
may also benefit dual eligibles with HIV.
This study has implications beyond Medicare part D 
and dual eligibles with HIV. Medicare part D’s privatized, 
market-based prescription drug plans are analogous to the 
privatized, market-based coverage that people with HIV en-
counter through the ACA’s Health Insurance Exchanges. An 
additional similarity is that the ACA allows ADAP to provide 
similar benefits for people with HIV as ADAP provided for 
dual eligibles under Medicare part D. These findings suggest 
that safety net programs such as ADAP may play a role in 
ensuring smooth insurance coverage transitions, an important 
consideration as people with HIV transition to private pre-
scription drug coverage under the ACA.
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